Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Neoplasms 9Sarcoma 5Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Endometrial Neoplasms 4Ovarian Neoplasms 3Solid Tumors 2Prostatic Neoplasms 2Multiple Myeloma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Bone Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Recurrence × ridaforolimus × Clear all
NCT01380184 2019-04-19

MK-8669-059

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled 15 charts

Neoplasms, Recurrence

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
24 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT00086125 2015-08-19

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
57 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

NCT01071304 2015-04-10

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Merck Sharp & Dohme LLC

Phase 1 Completed
16 enrolled

Neoplasm Metastasis, Recurrence

NCT00112372 2015-02-12

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
147 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡